Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

A recent study highlights an increased risk of thromboembolic events in metastatic lung cancer patients treated with immune ...

The risk of myocardial infarction (MI) and stroke in the postexacerbation period was calculated relative to the patient's baseline risk using the self-controlled case series approach. Conclusion ...

Discover the heightened thromboembolic risk for metastatic lung cancer patients on immune checkpoint inhibitors. Learn about ...